News Releases | Lexicon Pharmaceuticals, Inc.

Press Releases

Lexicon Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Sotagliflozin New Drug Application for the Treatment of Type 1 Diabetes	Jan 17, 2019
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	Dec 21, 2018
Lexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes	Dec 20, 2018
Lexicon Pharmaceuticals Announces Positive Topline Clinical Data for LX9211	Dec 18, 2018
FDA Advisory Committee to Review Investigational Sotagliflozin as Potential Treatment for Type 1 Diabetes	Nov 29, 2018
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	Nov 08, 2018
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference	Nov 06, 2018
Lexicon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides a Business Update	Nov 01, 2018
Lexicon Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call and Webcast on November 1, 2018	Oct 25, 2018
Lexicon Pharmaceuticals and Ipsen Biopharmaceuticals Canada Inc. Announce Health Canada Approval of Xermelo® (telotristat Ethyl) for the Treatment of Refractory Carcinoid Syndrome Diarrhea in Combination with Somatostatin Analog Therapy	Oct 16, 2018